Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a <i>post hoc</i> analysis of the OHZORA trial
OZR is an effective anti-TNF treatment for RA, regardless of RF and ACPA titres, and exhibits promise as a novel therapeutic option.
Authors
- Masao Katsushima (ORCID: https://orcid.org/0009-0007-0033-1757)
- Yoshiya Tanaka (ORCID: https://orcid.org/0000-0002-0807-7139)
- Yoichi Nakayama (ORCID: https://orcid.org/0000-0002-8130-4350)
- Masanao Kyuuma
- Motomu Hashimoto (ORCID: https://orcid.org/0000-0002-9241-060X)
- Rumiko Matsumoto
- Shunsuke Okamoto (ORCID: https://orcid.org/0000-0002-9465-0375)
- Tsutomu Takeuchi (ORCID: https://orcid.org/0000-0003-1111-8218)
- Ryu Watanabe (ORCID: https://orcid.org/0000-0002-1089-5296)
Institutions
- Taisho Pharmaceutical (Japan) (JP)
- University of Occupational and Environmental Health Japan (JP)
- Keio University (JP)
- Kyoto University (JP)
- Osaka City University (JP)
- Taisho Pharmaceutical (Japan) (JP)
- Osaka Metropolitan University (JP)
- Saitama Medical University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1093/rheumatology/keaf171
- Citations
- 2
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 2.72